Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2023 Results

Original from: Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Fourth Quarter and Full Year 2023 Highlights

·    Fourth quarter revenue was $10.89 billion, 5% lower versus the same quarter last year. Core organic revenue growth declined 4%.

·    Fourth quarter GAAP diluted EPS was $4.20, 5% higher versus the same quarter last year, driven by 70 basis points of operating margin expansion.

·    Fourth quarter adjusted EPS was $5.67, 5% higher versus the same quarter last year, driven by 100 basis points of adjusted operating margin expansion.

·    Full year revenue was $42.86 billion, 5% lower versus prior year. Core organic revenue growth was 1%.

·    Full year GAAP diluted earnings per share (EPS) was $15.45.

·    Full year adjusted EPS was $21.55.

·    During the year, we strengthened our industry leadership, advanced our trusted partner status with our customers, and delivered differentiated financial performance for our shareholders due to strong execution by our global team enabled by our PPI Business System.

·    Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the year, highlighted by the groundbreaking Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, the Applied Biosystems™ QuantStudio™ Absolute Q™ AutoRun dPCR System, the Thermo Scientific™ Metrios™ 6 S/TEM, the first FDA-cleared assays for risk assessment and clinical management of preeclampsia, and the Gibco™ CTS™ Detachable Dynabeads™. During the quarter, we launched the Thermo Scientific™ Meridian™ EX System, an electron-beam-based solution for precise defect localization in advanced logic semiconductors and the Thermo Scientific™ Aquanex™ Ultrapure Water Purification System, for reliable water purity and operational enhancement in laboratories.

·    Continued to further strengthen our industry-leading commercial engine and deepen our trusted partner status during the year, as demonstrated by our differentiated performance in 2023. This included the addition of a new customer excellence center in Europe, partnering and collaborating with customers on innovative new medicines, and leveraging digital tools to further optimize commercial effectiveness and improve the customer experience. During the fourth quarter, we opened a customer experience center for battery manufacturing in Seoul to support our material science customers as they accelerate the development of the next generation of environmentally friendly energy solutions.

·    Strong year advancing our corporate social responsibility (CSR) priorities. We accelerated our net-zero roadmap with on-site solar projects and power purchase agreements across the Americas, Europe and Asia Pacific regions, advancing our progress toward our target of utilizing 80% renewable electricity globally by 2030. We also progressed our global health equity initiatives by offering expanded access to advanced genomic testing in low- and middle-income countries and launched new initiatives to continue bringing clinical trials to historically underserved patient populations. We further engaged in supporting local communities through our colleague-led STEM education programs.

·    Continued to successfully execute our capital deployment strategy in 2023. During the year we completed the acquisitions of The Binding Site, a leading provider for detection and monitoring of multiple myeloma, and CorEvitas, a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. We also announced an agreement to acquire Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading solution for advanced proteomics discovery and development. Additionally, we returned $3.5 billion of capital to shareholders through stock buybacks and dividends.

“Thanks to the strong contributions from our team, we delivered differentiated performance in 2023 and enabled our customers’ success,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “We effectively navigated the challenging macroeconomic conditions by leveraging our PPI Business System to deliver strong financial results.”

Casper added, “Our proven growth strategy, capital deployment approach, and PPI Business System, continue to position our company for an even brighter future.”

Fourth Quarter 2023

Revenue for the quarter declined 5% to $10.89 billion in 2023, versus $11.45 billion in 2022. Organic revenue was 7% lower, Core organic revenue growth declined 4%, and COVID-19 testing revenue was $0.05 billion.

GAAP Earnings Results

GAAP diluted EPS in the fourth quarter of 2023 was $4.20, versus $4.01 in the same quarter last year. GAAP operating income for the fourth quarter of 2023 was $1.85 billion, compared with $1.86 billion in the year-ago quarter. GAAP operating margin was 17.0%, compared with 16.3% in the fourth quarter of 2022.

Non-GAAP Earnings Results

Adjusted EPS in the fourth quarter of 2023 was $5.67, versus $5.40 in the fourth quarter of 2022. Adjusted operating income for the fourth quarter of 2023 was $2.55 billion, compared with $2.56 billion in the year-ago quarter. Adjusted operating margin was 23.4%, compared with 22.4% in the fourth quarter of 2022.

Full Year 2023

Revenue for the full year declined 5% to $42.86 billion in 2023, versus $44.92 billion in 2022. Organic revenue was 5% lower, Core organic revenue growth was 1%, and COVID-19 testing revenue was $0.33 billion.

GAAP Earnings Results

GAAP diluted EPS for the full year was $15.45, versus $17.63 in 2022. GAAP operating income for 2023 was $6.86 billion, compared with $8.39 billion a year-ago. GAAP operating margin was 16.0%, compared with 18.7% in 2022.

Non-GAAP Earnings Results

Adjusted EPS for the full year was $21.55, versus $23.24 in 2022. Adjusted operating income for the full year was $9.81 billion, compared with $10.99 billion a year-ago. Adjusted operating margin was 22.9%, compared with 24.5% in 2022.

Annual Guidance for 2024

Thermo Fisher is initiating a guidance range for full year 2024 with revenue of $42.1 billion to $43.3 billion and adjusted EPS of $20.95 to $22.00.

​

Source: Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2023 Results